Literature DB >> 15030885

Determination of xylazine and its metabolites by GC-MS in equine urine for doping analysis.

M-H Spyridaki1, E Lyris, I Georgoulakis, D Kouretas, M Konstantinidou, C G Georgakopoulos.   

Abstract

Xylazine and its main metabolites were detected in equine urine after a single-dose intravenous administration of 0.98 and 1.01 mg/kg body weight xylazine, respectively, in two horses, in order to be used for equine doping control routine analysis. The urine levels of the parent drug and its metabolites were determined using gas chromatography-mass spectrometry (GC-MS). Xylazine is metabolised rapidly, down to a concentration level of about 1.0 microg/ml after 1-3h administration. Seven metabolites were identified in urine. 4-Hydroxy-xylazine, the major metabolite, could be traced for 25 h and it is regarded as the long-term metabolite of xylazine in horse. 2,6-Dimethylaniline was, for the first time, reported as metabolite in equine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15030885     DOI: 10.1016/j.jpba.2003.12.007

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  Liquid chromatography-tandem mass spectrometry analysis of anisodamine and its phase I and II metabolites in rat urine.

Authors:  Huaixia Chen; Hong Wang; Yong Chen; Huashan Zhang
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-09-25       Impact factor: 3.205

2.  Nanocoral-like Polyaniline-Modified Graphene-Based Electrochemical Paper-Based Analytical Device for a Portable Electrochemical Sensor for Xylazine Detection.

Authors:  Kasrin Saisahas; Asamee Soleh; Kiattisak Promsuwan; Jenjira Saichanapan; Apichai Phonchai; Nabeesathul Sumayya Mohamed Sadiq; Way Koon Teoh; Kah Haw Chang; Ahmad Fahmi Lim Abdullah; Warakorn Limbut
Journal:  ACS Omega       Date:  2022-04-12

3.  Serial-omics characterization of equine urine.

Authors:  Min Yuan; Susanne B Breitkopf; John M Asara
Journal:  PLoS One       Date:  2017-10-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.